Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cell Based Haploidentical Transplantation in High-Risk AML and MDS
NCT01370213Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Sep 2011
- Primary completion
- Apr 2016
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Natural Killer Cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Masonic Cancer Center. Started Sep 2011; status: completed.
02
Drugs
Natural Killer Cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01370213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01370213.